An Open-Label, Mulitcenter, First-in-Human, Dose Escalation, Phase 1 Study of ES002023 in Patients with Locally Advanced or Metastatic Solid Tumors
Fairfax Office
A Phase 2 multi-center open-label basket trial of ABI-009 (nab-sirolimus) for adult and adolescent patients with solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes
A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies